Get the Stockscreener App
1.98
1.96%
-0.06
Inflarx N V stock is traded at $1.98, with a volume of 53,383.
It is down -1.96% in the last 24 hours and up +30.72% over the past month.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
See More
Previous Close:
$2.04
Open:
$2.05
24h Volume:
53,383
Relative Volume:
0.40
Market Cap:
$116.59M
Revenue:
-
Net Income/Loss:
$-46.12M
P/E Ratio:
-2.6513
EPS:
-0.7468
Net Cash Flow:
$-41.02M
1W Performance:
-1.48%
1M Performance:
+30.72%
6M Performance:
+31.58%
1Y Performance:
+36.99%
1-Day Range:
$2.00
$2.08
1-Week Range:
$1.51
$2.37
52-Week Range:
$1.165
$2.44
Inflarx N V Stock (IFRX) Company Profile
Compare IFRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| IFRX | 2.00 | 116.59M | 0 | -46.12M | -41.02M | -0.7468 |
| VRTX | 446.61 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 740.52 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.00 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 250.23 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.42 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-05-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-28-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-06-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-08-20 | Initiated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Apr-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-05-19 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-05-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-05-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Jun-05-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-05-19 | Downgrade | SunTrust | Buy → Hold |
| Jan-29-19 | Initiated | Robert W. Baird | Outperform |
| Dec-10-18 | Initiated | Credit Suisse | Outperform |
| Jul-13-18 | Initiated | BMO Capital Markets | Outperform |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-28-18 | Initiated | SunTrust | Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Inflarx N V Stock (IFRX) Latest News
10 Best German Stocks To Buy Now - Insider Monkey
Is InflaRx N.V. (IFRX) the Best German Stock to Buy Now? - Yahoo Finance
Lucid Capital sets Inflarx NV Buy stock rating on clinical trial potential - Investing.com
InflaRx receives positive CHMP opinion for SARS-CoV-2-induced acute respiratory distress treatment - MSN
InflaRx's GOHIBIC gets EMA panel nod for COVID-19 ARDS By Investing.com - Investing.com Canada
InflaRx's GOHIBIC gets EMA panel nod for COVID-19 ARDS - Investing.com India
InflaRx’s GOHIBIC gets EMA panel nod for COVID-19 ARDS By Investing.com - ழ தொலைக்காட்சி
InflaRx Receives Positive CHMP Opinion for GOHIBIC® - GlobeNewswire
InflaRx's GOHIBIC Secures Key EU Backing for COVID ARDS Treatment After 24% Mortality Reduction | IFRX Stock News - StockTitan
FY2024 EPS Estimates for InflaRx Cut by Leerink Partnrs - Defense World
U.S. Stock market top gainers: Omeros Corporation gains 52.99% while InflaRx N.V surges by 40.94% - Business Upturn
FY2024 Earnings Forecast for InflaRx Issued By HC Wainwright - MarketBeat
FY2024 EPS Estimates for InflaRx Reduced by Leerink Partnrs - MarketBeat
Prenetics Global And 2 Other US Penny Stocks To Watch - Simply Wall St
InflaRx Reports Q3 2024 Financial Results and Progress - Yahoo Finance
InflaRx (NASDAQ:IFRX) Receives Buy Rating from HC Wainwright - MarketBeat
We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate - Yahoo Finance
InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
InflaRx Reports Rising Revenue Amidst Significant Losses - TipRanks
InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
InflaRx (IFRX) to Release Earnings on Friday - Defense World
InflaRx (IFRX) Set to Announce Quarterly Earnings on Friday - MarketBeat
InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference - The Manila Times
InflaRx to Report Third Quarter 2024 Financial Results on - GlobeNewswire
Critical Review: PDS Biotechnology (NASDAQ:PDSB) & InflaRx (NASDAQ:IFRX) - Defense World
InflaRx (NASDAQ:IFRX) Sees Significant Increase in Short Interest - MarketBeat
InflaRx shares maintain Buy rating from H.C. Wainwright on Gohibic trial analysis - Investing.com
InflaRx (NASDAQ:IFRX) Given Buy Rating at HC Wainwright - Defense World
InflaRx reports promising HS treatment results at EADV Congress - Investing.com India
InflaRx (NASDAQ:IFRX) Given "Buy" Rating at HC Wainwright - MarketBeat
InflaRx presents e-poster presentation of post hoc analysis of SHINE study - TipRanks
InflaRx Presents Post Hoc Analysis of SHINE Trial of - GlobeNewswire
InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 - EIN News
InflaRx Announces Participation in September Investor Events - Yahoo Finance UK
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases - Yahoo Finance UK
InflaRx (NASDAQ:IFRX) Stock Price Up 1.3% - MarketBeat
InflaRx (NASDAQ:IFRX) Shares Up 1.3% - Defense World
InflaRx reports promising data on oral C5aR inhibitor INF904 - Investing.com
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human - EIN News
InflaRx reports promising data on oral C5aR inhibitor INF904 By Investing.com - Investing.com UK
InflaRx presents new preclinical findings for INF904 - TipRanks
InflaRx Presents New Preclinical Findings for INF904 at the - GlobeNewswire
InflaRx (NASDAQ:IFRX) Short Interest Down 9.2% in August - MarketBeat
Short Interest in InflaRx (NASDAQ:IFRX) Rises By 281.4% - MarketBeat
InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
InflaRx N.V. Reports Mid-Year Financial Results - TipRanks
InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
InflaRx reports Q2 EPS (24c), consensus (22c) - TipRanks
InflaRx (IFRX) Set to Announce Earnings on Thursday - Defense World
InflaRx (IFRX) to Release Earnings on Thursday - MarketBeat
Inflarx N V Stock (IFRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):